Mapatumumab is a recombinant, high-affinity fully human agonist IgG monoclonal antibody that is specific for human TRAIL-R1, a protein that is overexpressed in a broad range of solid tumors ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...